Kintara announces correction to prior reverse stock split announcement

Kintara Therapeutics announced a correction to the press release previously issued by Kintara on October 16. Kintara’s board has approved a reverse stock split of Kintara’s common stock at a ratio of 1-for-35. Kintara’s common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, under the new name TuHURA Biosciences and under the new symbol “HURA” following the anticipated closing of the merger with TuHURA. This press release corrects the previous announcement which contained a scrivener’s error stating Kintara’s common stock was expected to begin trading on a post-reverse stock split basis on October 17; as correctly stated above, Kintara’s common stock is expected to begin trading on a post-reverse stock split basis on October 18, the company noted.